Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Intercept Pharmaceut (ICPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 3,186,274
  • Shares Outstanding, K 25,010
  • Annual Sales, $ 24,950 K
  • Annual Income, $ -412,830 K
  • 36-Month Beta -1.99
  • Price/Sales 128.96
  • Price/Cash Flow 0.00
  • Price/Book 13.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.05 +6.99%
on 07/03/17
133.73 -3.96%
on 06/26/17
-3.85 (-2.91%)
since 06/23/17
3-Month
104.33 +23.11%
on 05/31/17
133.73 -3.96%
on 06/26/17
+17.33 (+15.60%)
since 04/24/17
52-Week
96.63 +32.92%
on 11/04/16
177.93 -27.81%
on 08/01/16
-29.76 (-18.81%)
since 07/22/16

Most Recent Stories

More News
Is a Beat in Store for Agenus (AGEN) this Earnings Season?

Agenus Inc. (AGEN) will focus on the development of all its pipeline drugs as currently there are no marketed drug in its portfolio.

AGEN : 5.37 (+6.34%)
MRK : 62.57 (-0.10%)
GILD : 74.39 (+0.85%)
ICPT : 128.44 (+0.82%)
What to Expect from Keryx (KERX) this Earnings Season?

Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia...

AGEN : 5.37 (+6.34%)
KERX : 7.29 (+0.69%)
GILD : 74.39 (+0.85%)
ICPT : 128.44 (+0.82%)
Is a Beat in Store for Alexion (ALXN) this Earnings Season?

Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.

AGEN : 5.37 (+6.34%)
GILD : 74.39 (+0.85%)
ICPT : 128.44 (+0.82%)
ALXN : 130.74 (-0.80%)
Look for Shares of Intercept Pharma to Potentially Pullback after Yesterday's 1.71% Rise

Intercept Pharma (NYSE:ICPT) traded in a range yesterday that spanned from a low of $127.43 to a high of $131.55. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high...

ICPT : 128.44 (+0.82%)
Intercept's Ocaliva(R) (obeticholic acid) Receives 2017 Galien Chemical Synthesis Drug Award in Italy

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

ICPT : 128.44 (+0.82%)
Daily Technical Summary Reports on Biotech Stocks -- Illumina, Navidea Biopharma, Grifols, and Intercept Pharma

DailyStockTracker.com today reviews Illumina Inc. (NASDAQ: ILMN), Navidea Biopharmaceuticals Inc (NYSE MKT: NAVB), Grifols S.A. (NASDAQ: GRFS), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). According...

ILMN : 173.99 (+0.72%)
GRFS : 20.37 (-1.59%)
NAVB : 0.45 (-5.26%)
ICPT : 128.44 (+0.82%)
Intercept (ICPT) Releases Data from Phase II Flint Trial

Intercept Pharmaceuticals, Inc. (ICPT) announced a retrospective analysis of the phase II trial, FLINT, in patients who were diagnosed with nonalcoholic steatohepatitis (NASH) and type II diabetes.

VVUS : 1.20 (-3.23%)
MEIP : 3.04 (+0.66%)
ICPT : 128.44 (+0.82%)
SNY : 47.71 (unch)
Intercept Pharmaceuticals (ICPT) Looks Good: Stock Adds 5.3% in Session

Intercept Pharmaceuticals, Inc. (ICPT) was a big mover last session, as the company saw its shares rise over 5% on the day with a solid volume as well.

ICPT : 128.44 (+0.82%)
Today's Research Reports on Stocks to Watch: Rite Aid and Intercept Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / June 5, 2017 / U.S. markets continued to climb towards new record Friday, despite a disappointing jobs report. The Dow Jones Industrial Average increased 0.29 percent to close...

RAD : 2.49 (+0.40%)
ICPT : 128.44 (+0.82%)
Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada

Intercept Pharmaceuticals, Inc. (ICPT) announced that livver drug Ocaliva has obtained approval in Canada also.

VVUS : 1.20 (-3.23%)
NVS : 84.29 (-0.82%)
GILD : 74.39 (+0.85%)
ICPT : 128.44 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR)....

See More

Support & Resistance

2nd Resistance Point 130.64
1st Resistance Point 129.54
Last Price 128.44
1st Support Level 126.67
2nd Support Level 124.90

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.